Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Teniposide
Drug ID BADD_D02153
Description Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.
Indications and Usage Teniposide is used for the treatment of refractory acute lymphoblastic leukaemia
Marketing Status approved
ATC Code L01CB02
DrugBank ID DB00444
KEGG ID D02698
MeSH ID D013713
PubChem ID 5396
TTD Drug ID D01DBQ
NDC Product Code Not Available
UNII 957E6438QA
Synonyms Teniposide | Demethyl Epipodophyllotoxin Thenylidine Glucoside | Vumon | VM-26 | VM 26 | VM26 | Teniposide, (5a alpha,9 alpha(S*))-Isomer | NSC-122819 | NSC 122819 | NSC122819
Chemical Information
Molecular Formula C32H32O13S
CAS Registry Number 29767-20-2
SMILES COC1=CC(=CC(=C1O)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)OC6C(C(C7C(O6)COC(O7)C8=C C=CS8)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Acute leukaemia16.01.02.001; 01.10.02.001--Not Available
Acute myeloid leukaemia16.01.05.001; 01.10.05.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.001--Not Available
Blood pressure fluctuation24.06.01.002--Not Available
Body temperature increased13.15.01.001--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Cardiovascular disorder02.11.01.010; 24.03.02.009--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.001--
Chronic myeloid leukaemia16.01.07.001; 01.10.07.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Cyanosis22.02.02.007; 23.06.04.005; 02.11.04.004; 24.03.01.007--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dyspnoea22.02.01.004; 02.11.05.003--
Extravasation08.01.03.008--Not Available
Feeling abnormal08.01.09.014--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gastrointestinal pain07.01.05.005--
Haemoglobin13.01.05.018--Not Available
Haemolytic anaemia01.06.03.002--Not Available
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene